Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 74

1.

A Potent and Effective Suicidal Listeria Vaccine Platform.

Hanson WG, Benanti EL, Lemmens EE, Liu W, Skoble J, Leong ML, Rae CS, Fassò M, Brockstedt DG, Chen C, Portnoy DA, Dubensky TW Jr, Lauer P.

Infect Immun. 2019 Jul 23;87(8). pii: e00144-19. doi: 10.1128/IAI.00144-19. Print 2019 Aug.

2.

Cyclic Dinucleotide-Adjuvanted Dengue Virus Nonstructural Protein 1 Induces Protective Antibody and T Cell Responses.

Espinosa DA, Beatty PR, Reiner GL, Sivick KE, Hix Glickman L, Dubensky TW Jr, Harris E.

J Immunol. 2019 Feb 15;202(4):1153-1162. doi: 10.4049/jimmunol.1801323. Epub 2019 Jan 14.

PMID:
30642979
3.

Magnitude of Therapeutic STING Activation Determines CD8+ T Cell-Mediated Anti-tumor Immunity.

Sivick KE, Desbien AL, Glickman LH, Reiner GL, Corrales L, Surh NH, Hudson TE, Vu UT, Francica BJ, Banda T, Katibah GE, Kanne DB, Leong JJ, Metchette K, Bruml JR, Ndubaku CO, McKenna JM, Feng Y, Zheng L, Bender SL, Cho CY, Leong ML, van Elsas A, Dubensky TW Jr, McWhirter SM.

Cell Rep. 2018 Dec 11;25(11):3074-3085.e5. doi: 10.1016/j.celrep.2018.11.047.

4.

Combining STING-based neoantigen-targeted vaccine with checkpoint modulators enhances antitumor immunity in murine pancreatic cancer.

Kinkead HL, Hopkins A, Lutz E, Wu AA, Yarchoan M, Cruz K, Woolman S, Vithayathil T, Glickman LH, Ndubaku CO, McWhirter SM, Dubensky TW Jr, Armstrong TD, Jaffee EM, Zaidi N.

JCI Insight. 2018 Oct 18;3(20). pii: 122857. doi: 10.1172/jci.insight.122857.

5.

Recombinant Listeria promotes tumor rejection by CD8+ T cell-dependent remodeling of the tumor microenvironment.

Deng W, Lira V, Hudson TE, Lemmens EE, Hanson WG, Flores R, Barajas G, Katibah GE, Desbien AL, Lauer P, Leong ML, Portnoy DA, Dubensky TW Jr.

Proc Natl Acad Sci U S A. 2018 Aug 7;115(32):8179-8184. doi: 10.1073/pnas.1801910115. Epub 2018 Jul 23.

6.

STING-Activating Adjuvants Elicit a Th17 Immune Response and Protect against Mycobacterium tuberculosis Infection.

Van Dis E, Sogi KM, Rae CS, Sivick KE, Surh NH, Leong ML, Kanne DB, Metchette K, Leong JJ, Bruml JR, Chen V, Heydari K, Cadieux N, Evans T, McWhirter SM, Dubensky TW Jr, Portnoy DA, Stanley SA.

Cell Rep. 2018 May 1;23(5):1435-1447. doi: 10.1016/j.celrep.2018.04.003.

7.

TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.

Francica BJ, Ghasemzadeh A, Desbien AL, Theodros D, Sivick KE, Reiner GL, Hix Glickman L, Marciscano AE, Sharabi AB, Leong ML, McWhirter SM, Dubensky TW Jr, Pardoll DM, Drake CG.

Cancer Immunol Res. 2018 Apr;6(4):422-433. doi: 10.1158/2326-6066.CIR-17-0263. Epub 2018 Feb 22.

8.

New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31stAnnual Meeting of the Society for Immunotherapy of Cancer, 2016.

Adusumilli PS, Cha E, Cornfeld M, Davis T, Diab A, Dubensky TW Jr, Evans E, Grogan JL, Irving BA, Leidner RS, Olwill SA, Soon-Shiong P, Triebel F, Tuck D, Bot A, Dansey RD, Drake CG, Freeman GJ, Ibrahim R, Patel S, Chen DS.

J Immunother Cancer. 2017 Jun 20;5:50. doi: 10.1186/s40425-017-0253-2. eCollection 2017. Review.

9.

Comment on "The Common R71H-G230A-R293Q Human TMEM173 Is a Null Allele".

Sivick KE, Surh NH, Desbien AL, Grewal EP, Katibah GE, McWhirter SM, Dubensky TW Jr.

J Immunol. 2017 Jun 1;198(11):4183-4185. doi: 10.4049/jimmunol.1700294. No abstract available.

10.

A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.

Foote JB, Kok M, Leatherman JM, Armstrong TD, Marcinkowski BC, Ojalvo LS, Kanne DB, Jaffee EM, Dubensky TW Jr, Emens LA.

Cancer Immunol Res. 2017 Jun;5(6):468-479. doi: 10.1158/2326-6066.CIR-16-0284. Epub 2017 May 8.

11.

The host STING pathway at the interface of cancer and immunity.

Corrales L, McWhirter SM, Dubensky TW Jr, Gajewski TF.

J Clin Invest. 2016 Jul 1;126(7):2404-11. doi: 10.1172/JCI86892. Epub 2016 Jul 1. Review.

12.

STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia.

Curran E, Chen X, Corrales L, Kline DE, Dubensky TW Jr, Duttagupta P, Kortylewski M, Kline J.

Cell Rep. 2016 Jun 14;15(11):2357-66. doi: 10.1016/j.celrep.2016.05.023. Epub 2016 Jun 2.

13.

Antagonism of the STING Pathway via Activation of the AIM2 Inflammasome by Intracellular DNA.

Corrales L, Woo SR, Williams JB, McWhirter SM, Dubensky TW Jr, Gajewski TF.

J Immunol. 2016 Apr 1;196(7):3191-8. doi: 10.4049/jimmunol.1502538. Epub 2016 Feb 29.

14.

Radiotherapy Combined with Novel STING-Targeting Oligonucleotides Results in Regression of Established Tumors.

Baird JR, Friedman D, Cottam B, Dubensky TW Jr, Kanne DB, Bambina S, Bahjat K, Crittenden MR, Gough MJ.

Cancer Res. 2016 Jan 1;76(1):50-61. doi: 10.1158/0008-5472.CAN-14-3619. Epub 2015 Nov 13.

15.

Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination.

Jackson CM, Kochel CM, Nirschl CJ, Durham NM, Ruzevick J, Alme A, Francica BJ, Elias J, Daniels A, Dubensky TW Jr, Lauer P, Brockstedt DG, Baxi EG, Calabresi PA, Taube JM, Pardo CA, Brem H, Pardoll DM, Lim M, Drake CG.

Clin Cancer Res. 2016 Mar 1;22(5):1161-72. doi: 10.1158/1078-0432.CCR-15-1516. Epub 2015 Oct 21.

16.

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.

Corrales L, Glickman LH, McWhirter SM, Kanne DB, Sivick KE, Katibah GE, Woo SR, Lemmens E, Banda T, Leong JJ, Metchette K, Dubensky TW Jr, Gajewski TF.

Cell Rep. 2015 May 19;11(7):1018-30. doi: 10.1016/j.celrep.2015.04.031. Epub 2015 May 7.

17.

STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.

Fu J, Kanne DB, Leong M, Glickman LH, McWhirter SM, Lemmens E, Mechette K, Leong JJ, Lauer P, Liu W, Sivick KE, Zeng Q, Soares KC, Zheng L, Portnoy DA, Woodward JJ, Pardoll DM, Dubensky TW Jr, Kim Y.

Sci Transl Med. 2015 Apr 15;7(283):283ra52. doi: 10.1126/scitranslmed.aaa4306.

18.

Virological and preclinical characterization of a dendritic cell targeting, integration-deficient lentiviral vector for cancer immunotherapy.

Odegard JM, Kelley-Clarke B, Tareen SU, Campbell DJ, Flynn PA, Nicolai CJ, Slough MM, Vin CD, McGowan PJ, Nelson LT, Ter Meulen J, Dubensky TW Jr, Robbins SH.

J Immunother. 2015 Feb-Mar;38(2):41-53. doi: 10.1097/CJI.0000000000000067.

19.

Attenuated Listeria monocytogenes vectors overcome suppressive plasma factors during HIV infection to stimulate myeloid dendritic cells to promote adaptive immunity and reactivation of latent virus.

Miller EA, Spadaccia MR, Norton T, Demmler M, Gopal R, O'Brien M, Landau N, Dubensky TW Jr, Lauer P, Brockstedt DG, Bhardwaj N.

AIDS Res Hum Retroviruses. 2015 Jan;31(1):127-36. doi: 10.1089/AID.2014.0138.

20.

Rationale, progress and development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants.

Dubensky TW Jr, Kanne DB, Leong ML.

Ther Adv Vaccines. 2013 Nov;1(4):131-43. doi: 10.1177/2051013613501988. Review.

21.

A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice.

Keenan BP, Saenger Y, Kafrouni MI, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky TW Jr, Hassan R, Armstrong TD, Jaffee EM.

Gastroenterology. 2014 Jun;146(7):1784-94.e6. doi: 10.1053/j.gastro.2014.02.055. Epub 2014 Mar 6.

22.

Design of a novel integration-deficient lentivector technology that incorporates genetic and posttranslational elements to target human dendritic cells.

Tareen SU, Kelley-Clarke B, Nicolai CJ, Cassiano LA, Nelson LT, Slough MM, Vin CD, Odegard JM, Sloan DD, Van Hoeven N, Allen JM, Dubensky TW Jr, Robbins SH.

Mol Ther. 2014 Mar;22(3):575-587. doi: 10.1038/mt.2013.278. Epub 2013 Dec 6.

23.

Killed but metabolically active vaccines.

Dubensky TW Jr, Skoble J, Lauer P, Brockstedt DG.

Curr Opin Biotechnol. 2012 Dec;23(6):917-23. doi: 10.1016/j.copbio.2012.04.005. Epub 2012 May 18. Review.

PMID:
22608846
24.

A live-attenuated Listeria vaccine (ANZ-100) and a live-attenuated Listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction.

Le DT, Brockstedt DG, Nir-Paz R, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW Jr, Eiden JE, Jaffee EM, Laheru DA.

Clin Cancer Res. 2012 Feb 1;18(3):858-68. doi: 10.1158/1078-0432.CCR-11-2121. Epub 2011 Dec 6.

25.

Adjuvants for cancer vaccines.

Dubensky TW Jr, Reed SG.

Semin Immunol. 2010 Jun;22(3):155-61. doi: 10.1016/j.smim.2010.04.007. Epub 2010 May 21. Review.

PMID:
20488726
26.

Priming and activation of human ovarian and breast cancer-specific CD8+ T cells by polyvalent Listeria monocytogenes-based vaccines.

Sinnathamby G, Lauer P, Zerfass J, Hanson B, Karabudak A, Krakover J, Secord AA, Clay TM, Morse MA, Dubensky TW Jr, Brockstedt DG, Philip R, Giedlin M.

J Immunother. 2009 Oct;32(8):856-69. doi: 10.1097/CJI.0b013e3181b0b125.

PMID:
19752748
27.

Suppression of cell-mediated immunity following recognition of phagosome-confined bacteria.

Bahjat KS, Meyer-Morse N, Lemmens EE, Shugart JA, Dubensky TW, Brockstedt DG, Portnoy DA.

PLoS Pathog. 2009 Sep;5(9):e1000568. doi: 10.1371/journal.ppat.1000568. Epub 2009 Sep 4.

28.

Impact of preexisting vector-specific immunity on vaccine potency: characterization of listeria monocytogenes-specific humoral and cellular immunity in humans and modeling studies using recombinant vaccines in mice.

Leong ML, Hampl J, Liu W, Mathur S, Bahjat KS, Luckett W, Dubensky TW Jr, Brockstedt DG.

Infect Immun. 2009 Sep;77(9):3958-68. doi: 10.1128/IAI.01274-08. Epub 2009 Jun 15.

29.

Killed but metabolically active Bacillus anthracis vaccines induce broad and protective immunity against anthrax.

Skoble J, Beaber JW, Gao Y, Lovchik JA, Sower LE, Liu W, Luckett W, Peterson JW, Calendar R, Portnoy DA, Lyons CR, Dubensky TW Jr.

Infect Immun. 2009 Apr;77(4):1649-63. doi: 10.1128/IAI.00530-08. Epub 2009 Jan 21.

30.

KBMA Listeria monocytogenes is an effective vector for DC-mediated induction of antitumor immunity.

Skoberne M, Yewdall A, Bahjat KS, Godefroy E, Lauer P, Lemmens E, Liu W, Luckett W, Leong M, Dubensky TW, Brockstedt DG, Bhardwaj N.

J Clin Invest. 2008 Dec;118(12):3990-4001. doi: 10.1172/JCI31350. Epub 2008 Nov 6.

31.

Promises and challenges for the development of Listeria monocytogenes-based immunotherapies.

Brockstedt DG, Dubensky TW.

Expert Rev Vaccines. 2008 Sep;7(7):1069-84. doi: 10.1586/14760584.7.7.1069. Review.

PMID:
18767955
32.

Listeria monocytogenes multidrug resistance transporters activate a cytosolic surveillance pathway of innate immunity.

Crimmins GT, Herskovits AA, Rehder K, Sivick KE, Lauer P, Dubensky TW Jr, Portnoy DA.

Proc Natl Acad Sci U S A. 2008 Jul 22;105(29):10191-6. doi: 10.1073/pnas.0804170105. Epub 2008 Jul 16.

33.

Constitutive Activation of the PrfA regulon enhances the potency of vaccines based on live-attenuated and killed but metabolically active Listeria monocytogenes strains.

Lauer P, Hanson B, Lemmens EE, Liu W, Luckett WS, Leong ML, Allen HE, Skoble J, Bahjat KS, Freitag NE, Brockstedt DG, Dubensky TW Jr.

Infect Immun. 2008 Aug;76(8):3742-53. doi: 10.1128/IAI.00390-08. Epub 2008 Jun 9.

34.

Plasmid DNA-based alphavirus expression vectors for nucleic acid immunization.

Driver DA, Polo JM, Belli BA, Banks TA, Hariharan M, Dubensky TW Jr.

IDrugs. 1998 Oct;1(6):678-85.

PMID:
18465622
35.

Activation of immature hepatic NK cells as immunotherapy for liver metastatic disease.

Bahjat KS, Prell RA, Allen HE, Liu W, Lemmens EE, Leong ML, Portnoy DA, Dubensky TW Jr, Brockstedt DG, Giedlin MA.

J Immunol. 2007 Dec 1;179(11):7376-84.

36.

Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination.

Sawyer L, Hanson D, Castro G, Luckett W, Dubensky TW Jr, Stassinopoulos A.

Transfusion. 2007 Jun;47(6):1062-70.

PMID:
17524098
37.

Role of PD-1 and its ligand, B7-H1, in early fate decisions of CD8 T cells.

Goldberg MV, Maris CH, Hipkiss EL, Flies AS, Zhen L, Tuder RM, Grosso JF, Harris TJ, Getnet D, Whartenby KA, Brockstedt DG, Dubensky TW Jr, Chen L, Pardoll DM, Drake CG.

Blood. 2007 Jul 1;110(1):186-92. Epub 2007 Mar 28.

38.

Cytosolic entry controls CD8+-T-cell potency during bacterial infection.

Bahjat KS, Liu W, Lemmens EE, Schoenberger SP, Portnoy DA, Dubensky TW Jr, Brockstedt DG.

Infect Immun. 2006 Nov;74(11):6387-97. Epub 2006 Sep 5.

39.

Interferon-producing killer dendritic cells provide a link between innate and adaptive immunity.

Chan CW, Crafton E, Fan HN, Flook J, Yoshimura K, Skarica M, Brockstedt D, Dubensky TW, Stins MF, Lanier LL, Pardoll DM, Housseau F.

Nat Med. 2006 Feb;12(2):207-13. Epub 2006 Jan 29.

PMID:
16444266
40.

Selective targeting of antitumor immune responses with engineered live-attenuated Listeria monocytogenes.

Yoshimura K, Jain A, Allen HE, Laird LS, Chia CY, Ravi S, Brockstedt DG, Giedlin MA, Bahjat KS, Leong ML, Slansky JE, Cook DN, Dubensky TW, Pardoll DM, Schulick RD.

Cancer Res. 2006 Jan 15;66(2):1096-104.

41.

Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity.

Brockstedt DG, Bahjat KS, Giedlin MA, Liu W, Leong M, Luckett W, Gao Y, Schnupf P, Kapadia D, Castro G, Lim JY, Sampson-Johannes A, Herskovits AA, Stassinopoulos A, Bouwer HG, Hearst JE, Portnoy DA, Cook DN, Dubensky TW Jr.

Nat Med. 2005 Aug;11(8):853-60. Epub 2005 Jul 24.

PMID:
16041382
42.

Listeria-based cancer vaccines that segregate immunogenicity from toxicity.

Brockstedt DG, Giedlin MA, Leong ML, Bahjat KS, Gao Y, Luckett W, Liu W, Cook DN, Portnoy DA, Dubensky TW Jr.

Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13832-7. Epub 2004 Sep 13.

43.

Listeria monocytogenes as a vaccine vector: virulence attenuation or existing antivector immunity does not diminish therapeutic efficacy.

Starks H, Bruhn KW, Shen H, Barry RA, Dubensky TW, Brockstedt D, Hinrichs DJ, Higgins DE, Miller JF, Giedlin M, Bouwer HG.

J Immunol. 2004 Jul 1;173(1):420-7.

44.
45.

An alphavirus replicon particle chimera derived from venezuelan equine encephalitis and sindbis viruses is a potent gene-based vaccine delivery vector.

Perri S, Greer CE, Thudium K, Doe B, Legg H, Liu H, Romero RE, Tang Z, Bin Q, Dubensky TW Jr, Vajdy M, Otten GR, Polo JM.

J Virol. 2003 Oct;77(19):10394-403.

46.

A highly efficient gene delivery system derived from feline immunodeficiency virus (FIV).

Sauter SL, Gasmi M, Dubensky TW Jr.

Methods Mol Med. 2003;76:405-32. No abstract available.

PMID:
12526177
47.

Generation of retroviral packaging and producer cell lines for large-scale vector production with improved safety and titer.

Dubensky TW Jr, Sauter SL.

Methods Mol Med. 2003;76:309-30. No abstract available.

PMID:
12526171
48.

Alphavirus-based DNA vaccine breaks immunological tolerance by activating innate antiviral pathways.

Leitner WW, Hwang LN, deVeer MJ, Zhou A, Silverman RH, Williams BR, Dubensky TW, Ying H, Restifo NP.

Nat Med. 2003 Jan;9(1):33-9. Epub 2002 Dec 23.

49.

Virus-based vectors for human vaccine applications.

Polo JM, Dubensky TW Jr.

Drug Discov Today. 2002 Jul 1;7(13):719-27. Review.

PMID:
12110228

Supplemental Content

Loading ...
Support Center